New Delhi, Jan 8 (PTI) Drug firm Orchid Pharma today said it has received Establishment Inspection Report (EIR) from the US health regulator for its Chennai facility. Also Read - Lalu Yadav Under Observation At AIIMS, Nitish Kumar Wishes Him Speedy Recovery

The company has received the EIR from the United States Food and Drug Administration (USFDA) on successful inspection closure for the post-marketing adverse drug experience reporting inspection (PADE) conducted at Nungambakkam, Chennai facility, Orchid Pharma said in a BSE filing. Also Read - Nirmala Sitharaman Hosts Halwa Ceremony Ahead of Budget 2021 | Here's All You Need to Know

“The facility was inspected by USFDA in the month of June, 2017, it added. Also Read - AAP MLA Somnath Bharti Sentenced to Two Years in Jail For Assaulting Security Staff at AIIMS

As per the USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.

Shares of Orchid Pharma today closed 4.93 per cent higher at Rs 23.40 per scrip on BSE.

This is published unedited from the PTI feed.